Gonadal Failure with Cyclophosphamide Therapy for Lupus Nephritis: Advances in Fertility Preservation

Rheumatic Disease Clinics of North America

Volumn 36, Issue 1, 2010, Pages 99-108

  Mersereau, Jennifer ^a   Dooley, Mary Anne ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Gonadotropin releasing hormone agonist; Intravenous cyclophosphamide therapy; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ESTRADIOL; GONADORELIN AGONIST; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROCARBAZINE; TESTOSTERONE;

AMENORRHEA; CHILDHOOD CANCER; CLINICAL TRIAL; CRYOPRESERVATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; EMBRYO CULTURE; FEMALE FERTILITY; GONAD FUNCTION; HUMAN; HYPOGONADISM; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; OVARY DISEASE; OVARY FUNCTION; PATHOPHYSIOLOGY; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANIMALS; CYCLOPHOSPHAMIDE; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFERTILITY, FEMALE; INFERTILITY, MALE; INFUSIONS, INTRAVENOUS; LUPUS NEPHRITIS; MALE; OVARIAN FAILURE, PREMATURE; OVARY; RATS; REPRODUCTIVE TECHNIQUES, ASSISTED; SPERMATOZOA; YOUNG ADULT;

EID: 77349084879     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2009.12.010     Document Type: Review

References (59)

1. Fraenkel L., Bogardus S., and Concato J. Patient preferences for treatment of lupus nephritis. Arthritis Rheum 47 4 (2002) 421-428
2. Gourley M.F., Austin III H.A., Scott D., et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125 7 (1996) 549-557
3. Ioannidis J.P., Katsifis G.E., Tzioufas A.G., et al. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 29 10 (2002) 2129-2135
4. McDermott E.M., and Powell R.J. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 55 4 (1996) 224-229
5. Mok C.C., Wong R.W., and Lau C.S. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 42 6 (1999) 1274-1280
6. Belmont H.M., Storch M., Buyon J., et al. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 4 2 (1995) 104-108
7. Boumpas D.T., Austin III H.A., Vaughan E.M., et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119 5 (1993) 366-369
8. Kumar R., Biggart J.D., McEvoy J., et al. Cyclophosphamide and reproductive function. Lancet 1 7762 (1972) 1212-1214
9. Uldall P.R., Kerr D.N., and Tacchi D. Sterility and cyclophosphamide. Lancet 1 7752 (1972) 693-694
10. Wang C.L., Wang F., and Bosco J.J. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 4 1 (1995) 11-14
11. Warne G.L., Fairley K.F., Hobbs J.B., et al. Cyclophosphamide-induced ovarian failure. N Engl J Med 289 22 (1973) 1159-1162
12. Langevitz P., Klein L., Pras M., et al. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 28 3-4 (1992) 157-158
13. Park M.C., Park Y.B., Jung S.Y., et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 13 8 (2004) 569-574
14. Huong D.L., Amoura Z., Duhaut P., et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29 12 (2002) 2571-2576
15. Medeiros M.M., Silveira V.A., Menezes A.P., et al. Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res 34 12 (2001) 1561-1568
16. Johnson J., Canning J., Kaneko T., et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 428 6979 (2004) 145-150
17. Lee H.J., Selesniemi K., Niikura Y., et al. Bone marrow transplantation generates immature oocytes and rescues long-term fertility in a preclinical mouse model of chemotherapy-induced premature ovarian failure. J Clin Oncol 25 22 (2007) 3198-3204
18. Ataya K., Pydyn E., Young J., et al. The uptake and metabolism of cyclophosphamide by the ovary. Sel Cancer Ther 6 2 (1990) 83-92
19. Jarrell J., Lai E.V., Barr R., et al. Ovarian toxicity of cyclophosphamide alone and in combination with ovarian irradiation in the rat. Cancer Res 47 9 (1987) 2340-2343
20. Ataya K.M., Valeriote F.A., and Ramahi-Ataya A.J. Effect of cyclophosphamide on the immature rat ovary. Cancer Res 49 7 (1989) 1660-1664
21. Delrio G., De Placido S., Pagliarulo C., et al. Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori 72 1 (1986) 53-61
22. Ataya K.M., McKanna J.A., Weintraub A.M., et al. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 45 8 (1985) 3651-3656
23. Chemaitilly W., Mertens A.C., Mitby P., et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 91 5 (2006) 1723-1728
24. Nicosia S.V., Matus-Ridley M., and Meadows A.T. Gonadal effects of cancer therapy in girls. Cancer 55 10 (1985) 2364-2372
25. Stillman R.J., Schinfeld J.S., Schiff I., et al. Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol 139 1 (1981) 62-66
26. Callis L., Nieto J., Vila A., et al. Chlorambucil treatment in minimal lesion nephrotic syndrome: a reappraisal of its gonadal toxicity. J Pediatr 97 4 (1980) 653-656
27. Parra A., Santos D., Cervantes C., et al. Plasma gonadotropins and gonadal steroids in children treated with cyclophosphamide. J Pediatr 92 1 (1978) 117-124
28. Chemes H.E. Infancy is not a quiescent period of testicular development. Int J Androl 24 1 (2001) 2-7
29. Thomson A.B., Campbell A.J., Irvine D.C., et al. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet 360 9330 (2002) 361-367
30. Kuhajda F.P., Haupt H.M., Moore G.W., et al. Gonadal morphology in patients receiving chemotherapy for leukemia. Evidence for reproductive potential and against a testicular tumor sanctuary. Am J Med 72 5 (1982) 759-767
31. Meistrich M.L. Male gonadal toxicity. Pediatr Blood Cancer 53 2 (2009) 261-266
32. van Casteren N.J., van der Linden G.H., Hakvoort-Cammel F.G., et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer 52 1 (2009) 108-112
33. Meistrich M.L., Wilson G., Brown B.W., et al. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer 70 11 (1992) 2703-2712
34. Masala A., Faedda R., Alagna S., et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 126 4 (1997) 292-295
35. Ataya K., and Ramahi-Ataya A. Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod Toxicol 7 3 (1993) 229-235
36. Clowse M.E., Behera M.A., Anders C.K., et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 18 3 (2009) 311-319
37. Blumenfeld Z., Shapiro D., Shteinberg M., et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 9 6 (2000) 401-405
38. Somers E.C., Marder W., Christman G.M., et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52 9 (2005) 2761-2767
39. Blumenfeld Z., and Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monographs 34 (2005) 40-43
40. Ismail-Khan R., Minton S., Cox C., et al. Preservation of ovarian function in young women treated with neoadjuvant chmotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy [abstract]. J Clin Oncol 26 (2008) 54
41. Barbieri R., Yeh J., and Ravnikar V.A. GnRH agonists and ovarian hyperstimulation. Fertil Steril 56 2 (1991) 376-377
42. Hampton H.L., Whitworth N.S., and Cowan B.D. Gonadotropin-releasing hormone agonist (leuprolide acetate) induced ovarian hyperstimulation syndrome in a woman undergoing intermittent hemodialysis. Fertil Steril 55 2 (1991) 429-431
43. Johansen J.S., Riis B.J., Hassager C., et al. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 67 4 (1988) 701-706
44. Matta W.H., Shaw R.W., Hesp R., et al. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol (Oxf) 29 1 (1988) 45-51
45. Gerhard I., Schindler A.E., Buhler K., et al. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. Clin Ther 14 Suppl A (1992) 3-16
46. Roberts J.E., and Oktay K. Fertility preservation: a comprehensive approach to the young woman with cancer. J Natl Cancer Inst Monogr 34 (2005) 57-59
47. Veeck L.L., Bodine R., Clarke R.N., et al. High pregnancy rates can be achieved after freezing and thawing human blastocysts. Fertil Steril 82 5 (2004) 1418-1427
48. Practice Committee of the Society for Assisted Reproductive Technology, and Practice Committee of the American Society for Reproductive Medicine. Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion. Fertil Steril 88 6 (2007) 1495-1496
49. Stachecki J.J., and Cohen J. An overview of oocyte cryopreservation. Reprod Biomed Online 9 2 (2004) 152-163
50. Oktay K., Cil A.P., and Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 86 1 (2006) 70-80
51. Grifo J.A., and Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril 93 2 (2010) 391-396
52. Oktay K., Hourvitz A., Sahin G., et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 91 10 (2006) 3885-3890
53. Elizur S.E., Chian R.C., Pineau C.A., et al. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford) 47 10 (2008) 1506-1509
54. Boumpas D.T., Austin III H.A., Vaughn E.M., et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340 8822 (1992) 741-745
55. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 350 10 (2004) 971-980
56. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46 8 (2002) 2121-2131
57. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose versus high-dose intravenous cyclophosphamide. Ann Rheum Dis 69 1 (2010) 61-64
58. Grootscholten C., Bajema I.M., Florquin S., et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 56 3 (2007) 924-937
59. Appel G.B., Contreras G., Dooley M.A., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20 5 (2009) 1103-1112